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ABSTRACT OF THESIS 
 
 
INVESTIGATION OF THIOL-CONTAINING BIOMARKERS AND THEIR ROLE 
IN THE EXPOSOME 
  
Exposomics is an emerging area of study that looks at how the environment 
around a person or persons affects their overall health. Biomarkers have emerged 
as useful tools to better understand how the exposome affects a person. In this 
work, we investigate two potential endogenous biomarkers, homocysteine and 
glutathione that have been previously implicated in a number of diseases that have 
been linked to environmental causes. We also investigated an environmental 
exposure, the fungicide Ziram, which epidemiologically has been linked to 
diseases. In our investigation, we utilized capillary electrophoresis and capillary 
electrophoresis-mass spectrometry to develop a method for homocysteine and 
identify a derivative to keep it from auto-oxidizing. We utilized mass spectrometry 
to identify the best ionization technique to detect Ziram and confirmation of where 
it binds on thiol-containing molecules. We also developed a method to extract 
glutathione-Ziram from serum and utilized liquid chromatography-mass 
spectrometry to begin a validation of glutathione-Ziram. Although future work is 
needed, we believe that this work was the beginning steps to understand 
biomarkers and their role in the exposome.   
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CHAPTER 1.  INTRODUCTION 
 EXPOSOME 
  Christopher Paul Wild first coined the word ‘exposome’ in 2005 to describe 
the effect the environment has on the human genome and the potential for 
disease and disorder development.1 The exposome entails the life-course 
exposures that include everything from where we live to what we eat throughout 
our life from the prenatal to death.1,2 There are three categories of the exposome, 
the internal, general external, and specific external.1–3 The internal environment 
encompasses things like metabolism, endogenous hormones, gut microflora, and 
other things that are internal to a specific person.2 The specific external has to do 
with things like lifestyle factors, diet, environmental pollutants, and the general 
external involves socioeconomic status, urban-rural environment, and climate to 
name a few.2 All three categories are not mutually exclusive, but rather give an 
idea as to what a potential exposure is for a person and how that exposure can 
affect them and others in similar situations. Being able to understand the 
epidemiology and role a person’s environment can play on their health, could 
potentially link these complex health issues and how to understand them more.  
 There are two different approaches to measuring a person’s exposome, a 
bottom-up and top-down approach. The bottom-up approach essentially looks at 
particular chemicals of every individual ‘exposure’ (e.g. diet, pollution, etc) at 
multiple time points in a person’s life. Although this approach would be able to 
identify particular exposures, it would not take into account the internal 
environment and its role in the exposome. The top-down approach, on the other 
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hand, would look at all chemicals, or their metabolites, in the blood of an 
individual.4  One of the main advantages of this approach is that the exposure 
chemical could be monitored directly and/or the downstream effects of it. These 
downstream effects lead to signatures and biomarkers, which could ultimately 
lead to an understanding of disease progression.4 The discovery and usage of 
biomarkers, which aid in monitoring normal biological processes and pathogenic 
progression, has grown over the decades.5–7 However, the issue with intersecting 
the exposome with diseases while using biomarkers, is trying to intersect the 
biomarkers of a disease with the biomarkers of an exposure.  
 For instance, Parkinson’s Disease etiology has three different 
components: genetic-, age-, and environmental-related, so trying to establish a 
biomarker that can be indicative of Parkinson’s Disease across all three 
components is difficult.8 There may be one biomarker within the body that 
indicates the potential for Parkinson’s development from a genomic perspective, 
and another exogenous biomarker indicative of Parkinson’s from an 
environmental side. In some instances, the interaction between an exogenous 
and endogenous biomarker could be utilized in disease progression research. In 
this work, two endogenous and one exogenous biomarkers were investigated, 
homocysteine (HCYS), glutathione (GSH), and Ziram, respectively. Both 
homocysteine and glutathione have been implicated in a number of biological 
processes that can ultimately lead to diseases. The interaction between Ziram 
and glutathione was investigated to combine the exposome with biological 
processes in potential disease progression.  
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 ANALYTICAL TECHNIQUES 
One of the things to consider when looking at biomarkers is what type of 
separation technique to use for both qualitative and quantitative analysis. In this 
work, two separation techniques were used to look at the potential biomarkers of 
homocysteine and glutathione. These techniques were Capillary Electrophoresis 
(CE)/Capillary Electrophoresis-Mass Spectrometry (CE-MS) and Liquid 
Chromatography (LC)/Liquid Chromatography-Mass Spectrometry (LC-MS). 
 
 Capillary Electrophoresis 
Capillary electrophoresis (CE) is a separation technique that utilizes the 
ionization capabilities of the solute. A strong electric field is applied across the 
running buffer, allowing the ions to migrate depending on their size and electric 
charge.11 The advantages of CE is the short analysis time, high efficiency, small 
sample and separation buffer volumes, and ease of changing the separation 
buffer.11 The movement of the ions is a balancing act between the electromotive 
forces and frictional forces of the ion in the solution.12 A CE apparatus contains a 
very thin fused silica capillary suspended between two buffer solutions and a 
high-voltage power supply that is able to apply a separation voltage.11,12 Although 
CE has become more advanced, there are a few aspects to take into 
consideration when using this technique. One such aspect is the electroosmotic 
flow, or EOF. The inside of the capillary is covered with silanol groups that 
generally carry a negative charge due to the deprotonation of these groups.11,12 
Because of this negative charge, the cations in the solutions end up forming a 
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double layer, where the first layer is mostly immobilized due to the electrostatic 
interaction with the wall, and the second layer is more mobile and thus, along 
with the surrounding water molecules, are able to migrate to the cathode when 
the voltage is applied.11,12 The water molecules cause the whole solution in the 
capillary to be dragged forward, generating a net flow across the capillary.12 This 
flow allows the sample to move through the column more efficiently similarly to a 
plug, becoming an advantage over the parabolic shape flow that occurs in HPLC, 
eliminating band broadening.11,12 However, one downfall to this phenomenon is if 
the EOF exceeds the mobilities of the ions, specifically the anions, all ions will be 
pushed towards the detection causing the analysis of both cations and anions.12 
However, the EOF can be altered by adjusting the pH of the running buffer, the 
viscosity of the solution, adding a radial field, adding a surfactant, or adding 
organic solvents.11 
 
 Liquid Chromatography 
Liquid chromatography is a physical separation technique with a liquid 
mobile phase and a stationary phase bed. The separation occurs based on 
sorption and desorption of the analyte with the stationary phase.13 There are 
many separation mechanisms, e.g. ion-exchange, size-exclusion, and 
adsorption, but most LC systems are the result of a mixture. Originally, 
chromatography utilized a polar stationary phase and a non-polar mobile phase 
called normal-phase chromatography.13,14 However, as the technique has 
evolved, more and more LC systems utilize the reverse-phase chromatography, 
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which involves a non-polar stationary phase and a polar mobile phase. The 
stationary phase usually consists of a chemically bonded long hydrocarbon chain 
linked to a solid surface of silica.13,14 Some examples of these hydrocarbon 
chains are C8 and C18. These cause the main interaction between the stationary 
phase and analytes to be the hydrophobic forces. The retention of the analyte on 
the stationary phase depends on the surface area between the two. Thus, 
analytes with larger hydrophobic surface areas tend to stay longer on the column 
than smaller analytes.13,14 
The basic components of a liquid chromatography system are a solvent 
supply system, a pumping system, an injector, the column, and a detector.13,14 
The solvent supply system supplies the solvent to the system that acts as the 
mobile phase. The pumping system not only pumps the solvent through the 
system but also helps deliver a constant flow through the injector, column, and to 
the detector. The injector adds the mobile phase to a small volume of the analyte 
which is then injected onto the column. The column is where the actual 
separation occurs, and the detector is how the analyte is measured. Some 
systems are interfaced to a separate instrument that adds another identification 
ability. This is usually in terms of a mass spectrometer.  
 
 Mass Spectrometry 
Mass spectrometry has been coupled to many separation techniques to 
allow greater identification of molecules. In the case of both capillary 
electrophoresis and liquid chromatography, the liquid mobile phase is converted 
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to gas-phase ions where the analytes are further analyzed with the mass 
analyzer. Over the past few decades, the main ionization sources utilized in 
mass spectrometry are Atmospheric Pressure Chemical Ionization (APCI) and 
Electrospray Ionization (ESI).14,15 APCI was utilized as the main ionization source 
before ESI erupted in the field of LC-MS. Both ionization sources use some type 
of ionizing agent, e.g. reagent gaseous ions or high electric field, to energize the 
analyte for analysis. APCI and ESI are both considered soft ionization sources 
because when the analyte is impacted with the energy source, there is less 
fragmentation compared to hard sources and the molecular weight ion is seen in 
the spectrum.15,16 The ionization in APCI occurs by collision with ions produced 
by electron bombardment of a reagent gas.16 In the case of ESI, an analyte 
moves through a charged capillary causing ionization of the analyte.17  
Besides the ionization source, mass spectrometers follow a similar 
breakdown in their components. There is the inlet source, the ion source, the 
mass analyzer, the ion transducer, and the signal processor.16 The inlet source is 
how the sample is introduced into the mass spectrometer. It is usually coupled to 
a separation technique via tubing. The ion source is where the actual ionization 
of the analyte occurs. In both APCI and ESI, the ionization sources are at 
atmospheric pressure. The mass analyzer and ion transducer are contained 
within a vacuum pump system. The mass analyzer is similar to a filter that 
funnels the ions towards the transducer and can filter them based on their mass-
to-charge (m/z) ratio. The transducer converts the charged ions into electrical 
signals that can be processed by the computer.16   
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In this work, we attempted to identify analytical techniques for the 
identification of homocysteine, glutathione, Ziram, and the interaction of 
glutathione with Ziram. We utilized both Capillary Electrophoresis/Capillary 
Electrophoresis-Mass Spectrometry and Liquid Chromatography-Mass 
Spectrometry to measure the three compounds.  
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CHAPTER 2. HOMOCYSTEINE IDENTIFICATION VIA CAPILLARY 
ELECTROPHORESIS AND CAPILLARY ELECTROPHORESIS-MASS 
SPECTROMETRY 
 
 INTRODUCTION 
 Homocysteine is a noncanonical sulfur-containing amino acid that is not 
received through the diet, like other essential amino acids, nor is used to create 
proteins. However, homocysteine is created solely from methionine (Figure 2.1) 
as part of the methionine cycle, is converted into cysteine via the transsulfuration 
pathway, and can also be cyclized to form homocysteine thiolactone. 
Homocysteine (HCYS) has the chemical formula of C4H9NO2S, which is similar to 
cysteine, minus a methyl group, so the two homologues share chemical 
similarities (Figure 2.1). The main similarity between homocysteine and cysteine 
is the electronegative sulfur at the end of the side chain that can easily form 
disulfide bonds.  
   
Figure 2.1 Structure of a) homocysteine, b) cysteine, and c) methionine 
 
Methionine with adenosine triphosphate (ATP) is activated by methionine 
adenosyltransferase (MAT) to form S-adenosylmethionine (SAM/AdoMet), which 
H2N CH C
CH2
OH
O
CH2
c)
S
CH3
H2N CH C
CH2
OH
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SH
b)
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CH2
OH
O
CH2
SH
a)
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is used as a universal methyl donor. SAM is converted to S-
adenosylhomocysteine (SAH/AdoHcy) after donating a methyl group to DNA, 
RNA, and other proteins. SAH is then hydrolyzed to homocysteine and 
adenosine via SAH hydrolase (SAHH).18 Homocysteine is then irreversibly 
converted to cysteine via the transsulfuration pathway. Homocysteine condenses 
with serine to form cystathionine catalyzed by the pyridoxal-5’-phosphate (PLP)-
containing enzyme, cystathionine β-synthase (CBS). Cystathionine is then 
hydrolyzed to cysteine and α-ketobutyrate via a second PLP enzyme, γ-
cystathionase (CTH).19,20  
Besides being converted to cysteine as a regulatory mechanism, 
homocysteine can be remethylated back to methionine via two pathways. The 
first is a vitamin-B12 independent reaction where betaine has a methyl 
transferred to HCYS via betaine-homocysteine methyltransferase. The second is 
a vitamin-B12 dependent reaction where methionine synthase moves a methyl 
from 5-methyl tetrahydrofolate to HCYS. This leads to the formation of 
tetrahydrofolate (THF) as a byproduct that can be converted back to 5-methyl 
THF. The first reaction occurs in all tissues while the second occurs in the 
kidneys and liver.18–20 All of these pathways (Figure 2.2) are impacted by the B-
vitamin family.19,20 Because these pathways are so intricate, one misstep can 
cause a multitude of issues like diseases. 
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Figure 2.2 Homocysteine metabolism18 
 
 Homocysteine and diseases 
Homocysteine, although not a canonical amino acid, has been implicated 
as a biomarker in many diseases, such as cardiovascular diseases, autoimmune 
diseases, neurodegenerative diseases, and many more. Because HCYS is an 
intermediate in many pathways (Figure 2.2), any major concentration changes 
can indicate the progression of a disease or the likelihood of the development of 
a disease. Since homocysteine metabolism is considered part of the folate 
(vitamin B9) and cobalamin (Vitamin B12) pathways, if there is a deficiency in 
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either one of these vitamins or B6, there can be an increase in cellular 
homocysteine.9,21 As previously mentioned, there are mechanisms to lower 
HCYS levels in the cells. However, there can be issues if there are errors in the 
mechanism of HCYS metabolism, namely elevated levels of HCYS is referred to 
as hyperhomocysteinemia which can lead to homocystinuria, the inability to 
breakdown methionine.9  
 In the 1960s, a publication by K. McCully described vascular legions in 
two patients with homocystinuria. One was due to CBS deficiency and the other 
was due to a defect in cobalamin metabolism.9,22 Further cohort and ex vivo 
studies showed that elevated levels of HCYS is indicative of an increased risk of 
vascular disease. It has been shown that homocystinuria causes endothelial 
dysfunction and is due to reduced bioavailability of nitric oxide.22  
  Homocysteine has been implicated in other health issues like cognitive 
decline and diseases. Whether homocysteine plays a direct role in cognitive 
issues or is just an indication of the decline is unclear because of the involvement 
of the B-vitamins. Duan et al. compared increasing homocysteine levels in mice 
and human dopaminergic cell culture to determine their effect on dopaminergic 
neurons.23 They did not see a direct correlation between folate, homocysteine 
levels, and neuronal damage; but, they did see that the neurons became more 
susceptible to known Parkinson’s-causing toxins MPTP and rotenone.23 Another 
group, Isobe et al, investigated homocysteine metabolites and their effect on 
neurons. One of the products homocysteine is metabolized to is homocysteic 
acid, which is structurally similar to glutamate. Homocysteic acid activates the N-
12 
 
methyl-D-aspartate (NMDA) receptor similarly to glutamate, causing apoptosis of 
the neurons.24 They also saw that with activation of the NMDA receptor from 
homocysteic acid, the glutamate concentration increases, causing a reduction in 
glutathione, which leads to oxidative stress and ultimately apoptosis of the 
neurons.24  
 Although there have not been any major defining studies implicating 
homocysteine’s causation of diseases, there have been implications that a higher 
concentration means a greater susceptibility to many diseases. As a person 
ages, homocysteine levels also decrease, which only adds to the complexity of 
neurological decline and the development of other diseases. Normal 
homocysteine levels in blood and plasma are approximately 4-15 µM, so any 
deviation from this range can be quick and potentially detrimental.22,23 In this 
experiment, we attempted to identify homocysteine through capillary 
electrophoresis (CE) and capillary electrophoresis-mass spectrometry (CE-MS). 
We attempted to differentiate HCYS from the other sulfur-containing amino acids, 
cysteine and methionine utilizing CE and CE-MS.  
 
 MATERIALS AND METHODS 
  We used the Beckman Coulter P/ACE MDQ Capillary Electrophoresis 
System with a Didode array detector with a Polymicro technology column with an 
internal diameter of 50 µm and 32 Karat software. We also used the Groton 
Biosystems Crystal CE GPA100 system coupled to the Finnegan LCQ Deca 
Mass Spectrometer with Xcalibur software. We adjusted the Hudson protocol for 
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the capillary electrophoresis parameters.25 For the Beckman Coulter CE, we 
conditioned the column every day that a sample was to be run under the 
conditions in Table 2.1.  
Table 2.1 Column conditioning parameters for Capillary Electrophoresis 
Event Value Duration Inlet Vial Outlet Vial 
Rinse-
Pressure 
50 psi 5.00 min Methanol BGE 
out/waste 
Rinse-
Pressure 
50 psi 5.00 min DI Water BGE 
out/waste 
Rinse-
Pressure 
50 psi 2.00 min 1 M NaOH BGE 
out/waste 
Rinse-
Pressure 
50 psi 5.00 min DI Water BGE 
out/waste 
Rinse-
Pressure 
50 psi 5.00 min BGE buffer BGE 
out/waste 
Separate-
Pressure 
50 psi 30.00 min BGE buffer BGE 
out/waste 
 
The background electrolyte (BGE) buffer consisted of 192.5 µL formic acid 
in 100 mL deionized water with the pH adjusted to 2.85 with 50 mM ammonium 
formate. Samples were run under the conditions in Table 2.2. An absorbance at 
214 nm was used for all compounds. There was a multi-view screen to ensure 
that an absorbance was seen.  
Table 2.2 Run parameters for Capillary Electrophoresis 
Event Value Duration Inlet Vial Outlet Vial 
Rinse-
Pressure 
30 psi 5.00 min BGE buffer BGE out 
Rinse-
Pressure 
10 psi 5.00 min BGE buffer BGE out 
Inject-
Pressure 
0.7 psi 15.0 sec Sample BGE 
out/waste 
Inject-
pressure 
0.5 psi 10.0 sec  BGE buffer BGE 
out/waste 
Separate-
Voltage 
25.0 kV 20.00 min  BGE buffer BGE out 
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For the Groton-Finnegan system, the column was also conditioned every 
day a sample was going to be run under the following condition: 1 M NaOH, 1000 
mbar, 0.0 kV, 3.00 min. The samples were ran under the conditions in Table 2.3. 
Table 2.3 Run parameters for Capillary Electrophoresis-Mass Spectrometry 
Vial Pressure Voltage Time 
BGE buffer 1000 mbar 5.0 kV 3.00 min 
Sample 100 mbar 5.0 kV 0.20 min 
BGE buffer 50 mbar 25.0 kV 20.00 min 
 
 RESULTS AND DISCUSSIONS 
Because homocysteine has an overall negative charge due to the terminal 
sulfur, capillary electrophoresis is a good candidate for an analytical technique. 
Based on the Hudson protocol, we used lidocaine to assess the parameters in 
the protocol before attempting with HCYS.25 According to the protocol, the 
conditions for sample separation include working at a pressure of 50 and 75psi. 
Our system does not operate at that high of a pressure, so we used lidocaine to 
assess if our given pressure of 30psi would be sufficient. We also assessed the 
pressure and voltage applied over the course of the separation. Once all of the 
parameters were established for lidocaine, we started sampling homocysteine. 
As seen in Figure 2.3, we were able to get a good separation of homocysteine at 
an elution time of about eight minutes.  
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Figure 2.3 Electropherogram of homocysteine 
 
 Although the main goal of our experiment was to identify and potentially 
quantify homocysteine, we needed to consider similar compounds. These 
compounds included methionine, which homocysteine is part of that cycle, and 
cysteine, since homocysteine varies structurally by one methyl group. We looked 
at each one individually, then as homocysteine plus one of the others, and then 
as a combination of all three. As seen in Figure 2.4, all the compounds migrated 
about the same time with less than a half-minute difference. The inverted peak in 
both Figure 2.3 and 2.4 is due to a difference in the molar absorptivity coefficient 
from Beer’s Law. This could be due to the buffer absorbing better than the 
sample at the given wavelength. Since there was no differentiation between the 
three compounds, we looked to adding a derivatizing agent. 
Minutes
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Figure 2.4 Electropherogram of cysteine, homocysteine, and methionine 
  
We started looking at previous derivatizing agents that have been used 
with homocysteine, including 4-vinylpyridine. We originally started out at a 1:1 
mixture of 4-vinylpyridine to homocysteine, but the 4-vinylpyridine overtook the 
trace. Even after lowering the ratio of 4-vinylpyridine to homocysteine, the CE 
trace was still overpowered by the 4-vinylpyridine. Another derivatizing agent we 
looked at was N-ethylmaleimide (NEM, Figure 2.5), which has been shown to be 
an irreversible derivative that attaches to the sulfur across the double bond in 
sulfur-containing compounds.26 Although there was a peak when HCYS and 
NEM was ran on the CE, determining if the two molecules were actually 
combining was difficult. Therefore, the CE-MS was used to confirm that the 
compound was being formed. With a molecular weight of 260.31 g/mol, we used 
the CE-MS to look for the m/z indicating that compound. Our parameters for the 
CE-MS were as close to the CE as we could get, so that the differences between 
Methionine 
Cysteine 
Homocysteine 
Methionine + Cysteine + Homocysteine 
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the two instruments were miniscule. As seen in Figure 2.6, we were able to see 
the 261.3 m/z indicating that the NEM was attaching to the HCYS.  
 
 
 
 
Figure 2.5 Structure of N-ethylmaleimide 
 
 
Figure 2.6 Capillary Electrophoresis Mass Spectrum of homocysteine plus N-
ethylmaleimide 
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 CONCLUSION 
Homocysteine has emerged as a potential endogenous biomarker in a 
multitude of biological issues and diseases despite being a non-canonical amino 
acid. Because of the terminal sulfur group, capillary electrophoresis was utilized 
as the analytical technique to identify it. Even though we were able to identify 
HCYS via CE individually, the identification was made more difficult with the 
addition of similar compounds cysteine and methionine. This led to the 
investigation of using a derivatizing agent. The first one, 4-vinylpyridine, 
overpowered HCYS in the system, so we investigated the use of N-
ethylmaleimide. It was unclear if the HCYS and NEM were actually binding via 
use of the CE, so we coupled mass spectrometry with the CE to confirm. 
Through CE-MS, we were able to see the mass-to-charge ratio indicative of 
HCYS-NEM.  
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CHAPTER 3. ZIRAM IDENTIFICATION VIA LIQUID CHROMATOGRAPHY-
MASS SPECTROMETRY 
 INTRODUCTION 
Zinc (bis)dimethyldithiocarbamate, commonly known as Ziram (ZIR), is a 
potent fungicide of the dithiocarbamate (DTC) fungicide family. It includes 
Thiram, Zineb, Maneb, and many others. Dithiocarbamates were first discovered 
as plant fungicides in the 1930s  and first used during World War II.27 They have 
been used as plant fungicides, animal repellants, and in some cases as 
accelerants in the rubber industry.27 Ziram is part of a subset within this family of 
fungicides, the dialkyldithiocarbamates. One of the main features of these 
fungicides is the two sulfur groups that are highly reactive as seen in Figure 3.1. 
In some cases, like Ziram, they can act as chelating agents with a transition 
metal ion like zinc, manganese, and iron. These multisite interactions of these 
compounds give them an advantage to influence the biological activities of 
different proteins, enzymes, and exert pro-oxidant and, in some cases, 
antioxidant effects.27,28  
Zn
S
SS
S
N N
 
Figure 3.1 Structure of Ziram 
 
 The main toxicological effects of the DTC group is due to their lipophilic 
nature, allowing them to be easily absorbed through the skin, ingested, inhaled, 
and the ability to cross cell membranes.27 This capability, along with the chelation 
aspect, leads to the redistribution of heavy metals throughout the brain.28 
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Metabolically, DTCs undergo detoxification via S-glucuronidation or biodegrade 
to many metabolites such as carbon disulfide, thiourea, alkylamines, 
ethyleneamines, and many others.27,28 Carbon disulfide is a general neuropathic 
agent and ethylenethiourea, a biproduct of ethylenebis dithiocarbamates, has 
antithyroid and carcinogenic effects.27,28 There have also been studies on some 
of the DTC molecules that show they exhibit both antioxidant as well as pro-
oxidant effects.27  
Ziram, and other dithiocarbamates, have been implicated in having a role 
in the development of Parkinson’s disease among other diseases. Multiple 
epidemiology studies looking at farm workers exposed to Ziram indicated that a 
higher incidence of Parkinson’s or Parkinson-like symptoms occur later on in life 
compared to those not exposed to Ziram.29,30 Because DTCs have reactive 
sulfurs, an inference can be made that they are highly reactive to molecules with 
sulfurs, like homocysteine and glutathione.  
 Although there are new and emerging studies on the dithiocarbamates 
and their role in disease development and the exposome, there is a wide array of 
how to study these fungicides as potential biomarkers. In this study, we first 
investigated different ionization techniques to study Ziram, Electrospray 
Ionization (ESI) and Atmospheric Pressure Chemical Ionization (APCI) in positive 
and negative mode. We then looked at potential endogenous biomolecules, 
glutathione and insulin, that could interact with Ziram via Liquid Chromatography-
Mass Spectrometry.    
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 MATERIALS AND METHODS 
We used a Hewlett Packard series 1100 Liquid Chromatography system 
connected to a Mass Spectrometer Detector with Agilent ChemStation Software. 
We also used a Thermo Finnegan LTQ Mass Spectrometer and a Shimadzu 
Nexera Liquid Chromatographer coupled to a Thermo Q-Exactive (QE) Orbitrap 
Mass Spectrometer with a high temperature ESI source (HESI). Both the LTQ 
and Q-Exactive Mass Spectrometers were used with Xcalibur software. Infusion 
experiments on the LTQ utilized a syringe pump with a flow rate of 5 μL per 
minute. The spray voltage was set to 4.5 kV, the source current was 14 μA, the 
sheath auxiliary gas flow was 2 (arbitrary units), and the inlet temperature was 
250°C. The QE infusion experiments had a spray voltage set to 3.5-4 kV, the 
source current was 0.9 μA, the sheath auxillary gas flow was 2.8 arbitrary units, 
and the syringe pump flow rate was 3 μL per minute.  
 
 ESI versus APCI for Ziram detection 
A 1 mg/mL stock solution of Ziram in acetonitrile was diluted 1:10 in 
acetonitrile. The 1:10 diluted Ziram was injected on the HPLC under positive and 
negative mode for both ESI and APCI. Peak height, shape, area, and mass-to-
charge ratios were evaluated to determine which ionization technique would be 
optimal. The fragmentor, gain, gas temperature, voltage capillary, and nebulizer 
pressure were also investigated.  
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 Glutathione binding of Ziram 
Following the Kawakishi, S. et al protocol, 0.6 mmol of glutathione and 12 
mmol of phenyl-isothiocyanate was mixed in 5 mL deionized water. The pH was 
adjusted to 6 with HCl and NaOH, vortexed, and placed in a 70°C water bath for 
five hours. Ethyl acetate (2 mL) was added to the sample where it was then 
vortexed and centrifuged for two minutes. The ethyl acetate top layer was 
removed and the lower water layer was injected via flow injection analysis onto 
the LTQ.31 The same protocol was followed with a mixture of 4 millimolar 
glutathione and 80 millimolar Ziram in water.  
We made a solution of glutathione (0.1 mmol) and Ziram (20 mmol) in 2 
mL sodium phosphate buffer, pH 6 (10.105 g sodium phosphate dibasic, 1.697 g 
sodium phosphate monobasic, pH adjusted with HCl, and diluted to 500 mL with 
water). Along with a glutathione control, both samples were placed in a 37°C 
water bath. Starting at four hours, 100 microliters were removed, extracted with 
50 microliters ethyl acetate, diluted with 50 microliters water, and infused on the 
LTQ every hour until seven hours.  
 
 Insulin binding of Ziram 
The same protocol for the glutathione with Ziram was followed with 0.1 
mmol insulin and 20 mmol Ziram in sodium phosphate buffer. An insulin control 
was included with the sample, and both were incubated in a 37°C water bath for 
at least six hours. Ethyl acetate (200 μL) was added to 400 μL of sample, then 
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vortexed and centrifuged for two minutes. The ethyl acetate layer was removed 
and diluted with 400 μL water before infused on the LTQ.  
To cleave insulin, the University of Washington Proteomics Research 
protocol was used.32 Briefly, several mg/mL of insulin in 100 mM ammonium 
bicarbonate and 8 M urea was incubated with dithiothreitol (final concentration of 
5 mM) for 25-45 min at 56°C. The control was cooled to room temperature and 
spun down to collect the condensation. Ziram was added to one half of the 
control, and both the sample and control were incubated at 37°C for about an 
hour. The samples were diluted by a factor of 10 with 50:50 methanol:water and 
injected on the LTQ then for multiply charged ion confirmation on the Q-Exactive.   
 
 RESULTS AND DISCUSSION 
 ESI versus APCI for Ziram detection 
In the review by Crnogorac et al., different analytical techniques used to 
detect a number of dithiocarbamates was discussed.33 Among the techniques 
included electrospray ionization and atmospheric pressure chemical ionization, 
both in positive and negative mode. Each technique has pros and cons and 
seemed to give reliable results in the review. We wanted to test this out for Ziram 
specifically to determine which ionization technique and in which mode would 
yield better results. Although each technique was able to give us indicative peaks 
of Ziram, the main m/z ratio we were looking for was 120, which is just the 
dithiocarbamate of Ziram. Each ionization mode gave good indicative total ion 
chromatograms, with similar peak areas, shape, and height. However, the total 
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ion chromatogram of positive ESI was slightly better than the others (Figure 3.2). 
When looking at the average area and height for the total ion chromatograms 
and extracted ion chromatograms for m/z 120, ESI positive was slightly higher 
with less variation compared to the others (Table 3.1). Also, taking into 
consideration potential outside laboratories undertaking similar problems, most 
laboratories have at least instruments with ESI capabilities compared to APCI.  
 
 
Figure 3.2 Chromatograms of ESI negative, ESI positive, APCI negative, and 
APCI positive 
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Table 3.1 Average area and height for APCI negative, APCI positive, ESI 
negative, and ESI positive 
  Area 
  TIC 120 m/z 
  Average Std dev Average Std dev 
APCI neg 22204.08 28644.45 13721.3 16904.23 
APCI pos 432753.04 374569.19 39793.78 54258.24 
ESI neg 36493.86 47277.41 6171.41 4789.67 
ESI pos 463484.05 211371.49 32352.23 25136.78 
  Height 
  TIC 120 m/z 
  Average Std dev Average Std dev 
APCI neg 4859.48 5592.3 2893.1 3219.26 
APCI pos 82216.24 71831.25 10169.04 13664.54 
ESI neg 7478.46 8532.38 1699.22 1033.11 
ESI pos 88366.68 91177.11 7368.09 5630.78 
 
We also investigated within each technique some of the parameters 
involved, including the fragmentor value, the gain, gas temperature, voltage 
capillary, and nebulizer pressure. Overall peak shape, peak area, peak height, 
and overall mass-to-charge fragmentation were evaluated. For positive mode 
ESI, the optimal values we determined were 120 for the fragmentor, a 1.5 gain, 
30 psig nebulizer pressure, and 300°C gas temperature (Table 3.2). 
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Table 3.2 Optimized ESI and APCI parameters 
Parameter ESI positive ESI negative APCI 
positive 
APCI 
negative 
Drying gas 
flow 
11 L/min 11 L/min 11 L/min 11 L/min 
Nebulizer 
pressure 
30 psig 30 psig 30 psig 30 psig 
Drying gas 
temperature 
300°C 300°C 300°C 300°C 
Capillary 
voltage 
3500 V 3000 V 3000 V 3000 V 
Gain 1.5 1.5 N/A N/A 
Fragmentor 120 120 N/A N/A 
Corona 
Current 
N/A N/A 4.0 μA 15 μA 
 
 
 Glutathione binding of Ziram 
When we first started investigating Ziram, we wanted to look at potential 
endogenous biomarkers that would bind and carry the fungicide throughout the 
body. Because Ziram has the two reactive sulfurs, the molecules investigated 
would need to be endogenous to the human body and contain a sulfur to ensure 
that binding of Ziram to the molecule would most likely occur. This was also to be 
varied by looking at low-, medium-, and high-molecular weight molecules. 
Glutathione (Figure 3.3) was investigated as the low-molecular weight (307.32 
g/mol) molecule. Research has indicated that dithiocarbamates, like Ziram, would 
bind to other molecules via disulfide bonds, so glutathione, which contains one 
cysteine, was a viable candidate to investigate. To test this, we used the paper 
by Kawakishi, S. et al., where they used allyl isothiocyanate and glutathione.31 In 
our experiment, we used phenyl isothiocyanate and once injected on the LC-MS, 
major m/z peaks at 330 and 449 were observed. The 330 m/z ratio was attributed 
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to glutathione plus sodium, and the 449 m/z ratio was attributed to glutathione 
plus phenyl isocyanate and sodium. When we followed the same experiment with 
Ziram and allowed the solution to incubate for up to 7 hours, there was a change 
in the spectrum over the time frame. At zero-hour incubation, there were 
indicative peaks for glutathione and Ziram by themselves (Figure 3.4a and b). At 
the seven-hour mark, the m/z ratio of 120 revealing that Ziram and GSH were 
bonding (Figure 3.4c).  It was speculative at this point that the two molecules 
were bonding at the sulfurs.  
  
Figure 3.3 Structure of a) glutathione and b) glutathione disulfide  
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Figure 3.4 Mass spectra of a) glutathione before addition of Ziram, b) glutathione 
plus Ziram at 0 hours, and c) glutathione plus Ziram at 7 hours 
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The effect that the incubation time and temperature had on the binding and 
spectrum of the glutathione-Ziram (GSH-ZIR) solution was also examined. At the 
four-hour mark in the 70°C water bath, there were multiple ions indicative of 
glutathione plus Ziram. In comparison, a lower water bath temperature and 
longer incubation time was preferential for getting the indicative spectrum of 
GSH-ZIR. However, with both temperatures, there was a lot of extra peaks that 
were not easily identifiable as GSH, ZIR, or both.  
We then injected the glutathione-Ziram mixture on the LTQ to look at the 
fragment ions to confirm that the Ziram was attaching to the sulfur in glutathione. 
The major ions seen in the LTQ were Ziram plus glutathione and sodium and a 
peak indicative of cysteine and Ziram plus sodium, Figure 3.5. Although the 308 
m/z for GSH was seen in the spectrum, after the addition of Ziram, the relative 
abundance went down compared to before Ziram was added (Figure 3.6). The 
opposite was seen with the GSH-ZIR m/z of 427, which was more prevalent in 
the post-Ziram addition sample (Figure 3.7). Theoretically, GSH and Ziram 
should attach via a disulfide bond. However, the spectrum from the LTQ was not 
confirmatory, so the GSH-ZIR solution was infused onto the Q-Exactive and 
underwent tandem mass spectrometry. Under tandem mass spectrometry, GSH 
fragments at the peptide bonds. Ideally, even with the addition of Ziram attached 
at the cysteine, GSH-ZIR should still fragment at the peptide bonds. As seen in 
Figure 3.8, fragmentation at the glycine-cysteine peptide bond gives a peak at 
352.05 m/z. In Figure 3.9, the fragmenting at the glutamic acid and cysteine bond 
gives a peak at 297.04 m/z. Because there were no fragmentation peaks 
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suggesting that Ziram attached at any other place on GSH, we concluded that 
Ziram does attach at the sulfur in the cysteine.   
 
Figure 3.5 Full mass spectra from the LTQ of a) glutathione and b) glutathione 
plus Ziram 
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Figure 3.6 Mass spectra of 308 m/z for a) glutathione and b) glutathione plus 
Ziram 
 
Figure 3.7 Mass spectra of 427 m/z for a) glutathione and b) glutathione plus 
Ziram 
33 
 
 
 
Figure 3.8 a) Mass spectrum 353.05 m/z and b) fragmentation of 353.05m/z 
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Figure 3.9 a) Mass spectrum of 297.04 m/z and b) fragmentation of 297.04 m/z 
 
 Insulin binding of Ziram 
With the success of seeing Ziram bind to GSH, insulin was investigated 
next as the medium-sized molecular weight molecule. Insulin has a total 
molecular weight of 5733.62 g/mol and is made up of two chains, the a-chain and 
b-chain. The a-chain has a molecular weight of 2338.00 g/mol and four cysteine 
molecules. Two of the sulfurs connect to two cysteinyl sulfurs in the b-chain, 
which has a molecular weight of 3397.72 g/mol. Based on the results of GSH and 
Ziram, insulin could bind up to six Ziram at each sulfur. We followed the same 
experiment as GSH-ZIR to confirm that Ziram attaches to the cysteines in insulin; 
however, since insulin is heavier than GSH, we could not differentiate if Ziram 
a) 
b) 
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was attaching at the sulfurs or not on the LTQ. Because of this, we wanted to see 
if cleaving the two chains apart may enable us to see whether Ziram was binding 
at the cysteines or not. Following the WWPR-Proteomics Research Protocol, we 
were able to see what appeared to be multiply charged ions on the LTQ.32 
Although the LTQ was most likely showing multiply-charged ions, the Xcalibur 
software did not enable deconvolution (Figure 3.10). The insulin and insulin plus 
Ziram solutions were then infused on the Q-Exactive, which has similar software 
to the LTQ but can deconvolute spectra to show multiply charged ions in their 
singly charged states. After deconvolution, the spectrum showed that Ziram was 
attaching to the a-chain (Figure 3.11), b-chain (Figure 3.12), and the whole 
insulin molecule (Figure 3.13). However, if Ziram was truly attaching at the 
cysteines was unclear and further research would need to be done to breakdown 
the chains into smaller sections to confirm the actual location of Ziram binding to 
insulin. Some studies suggested that Ziram may cause reactive oxygen species 
with glutathione, especially in the brain, so further experiments were done with 
glutathione as the peptide of study.  
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Figure 3.10 Mass spectra of a) insulin and b) insulin plus Ziram on the LTQ 
 
Figure 3.11 Mass spectra of a) insulin a-chain and b) insulin a-chain plus Ziram 
on the Q-Exactive   
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Figure 3.12 Mass spectra of a) insulin b-chain and b) insulin b-chain plus Ziram 
on the Q-Exactive 
  
Figure 3.13 Mass spectra of a) insulin and b) insulin with Ziram on the Q-
Exactive 
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 CONCLUSION 
In this experiment, the two ionization techniques APCI and ESI were 
investigated as to which would be potentially better to detect Ziram on Liquid 
Chromatography-Mass Spectrometer. Both positive and negative polarity for 
each ionization technique was also investigated. Although all four modes, 
positive APCI, negative APCI, positive ESI, and negative ESI, gave reproducible 
results and would be good techniques to detect Ziram on the LC-MS, positive 
ESI gave slightly better chromatography. It was deemed to be the better option 
going forward. We then investigated the endogenous biomarkers glutathione and 
insulin to see if Ziram bonded to either of them. Because Ziram has reactive 
sulfurs, confirmation of where the binding was occurring was also investigated. 
Ziram was definitively seen to create a disulfide bond with the cysteinic sulfur in 
GSH via both the LTQ and QE. Although the LTQ and QE showed that Ziram 
appeared to attach to the insulin, whether the attachment occurred at the 
cysteines was not confirmed. Further research breaking down insulin more to 
confirm the binding of Ziram to the cysteines is needed. However, after some 
literature research, further experiments evaluated the Ziram and GSH interaction.     
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CHAPTER 4.  GLUTATHIONE AND ZIRAM METHOD DEVELOPMENT AND 
VALIDATION USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY 
 INTRODUCTION 
Glutathione (γ-glutamyl-cysteinyl-glycine) is a thiol containing tripeptide that 
is the most abundant low molecular weight peptide that was first identified over 
100 years ago and the structure officially identified in 1935.34 The peptide is fairly 
ubiquitous throughout animal tissues, plants, and microorganisms, accounting for 
about 90% of the total nonprotein sulfurs within cells.34 Due to the highly reactive 
sulfur on the cysteine, glutathione has been investigated as one of the most 
prevalent antioxidant scavengers in the body. Although the molecular weight is 
low (307.32 g/mol), the reactive sulfur and design of the peptide creates an 
interesting candidate as a redox buffer, maintaining enzymes and other cellular 
components in a reduced state. The glutamic acid is attached via the gamma 
linkage, which could protect the peptide from degradation by aminopeptidases.35 
 Glutathione (GSH) is synthesized intracellularly beginning with the 
attachment of γ-glutamic acid to cysteine via γ-glutamyl-cysteine synthetase.36,37 
Glycine is then added onto the carboxyl side to γ-glutamyl-cysteine via 
glutathione synthetase.36,37 The first reaction is inhibited by GSH. Glutathione is 
degraded extracellularly via γ-glutamyl transpeptidase and other dipeptidases 
where γ-glutamic acid is transferred to free amino acids and cysteinylglycine can 
be broken down to be replenished.36,37 These γ-glutamyl amino acids are 
transported into cells where they are converted to 5-oxoproline and subsequently 
glutamate via an ATP-dependent reaction (Figure 4.1).37  
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Figure 4.1 Glutathione metabolism.37 Enzymes include: 1, γ-glutamylcysteine 
synthetase; 2, GSH synthetase; 3, γ-glutamyltranspeptidase; 4, dipeptidases; 5, 
γ-glutamylcyclotransferase; 6, 5-oxoprolinase; 7, GSH S-transferases; 8, N-
acetyltransferase; 9, GSH thiol transferases 
 
 Glutathione and diseases 
Glutathione is one of the most important and abundant low molecular 
weight antioxidants in the human body because of the electronegative sulfur side 
chain on the cysteine.38 GSH plays an important role in many cellular reactions, 
including scavenging free radicals and reactive oxygen species, storage and 
transport of cysteine, and mitochondrial function and integrity to name a few.10,39 
Because of these many functions, especially oxidative stress, glutathione has 
been implicated as a biomarker in many diseases such as Parkinson’s Disease. 
As an antioxidant, reduced glutathione is converted to the oxidized form, GSSG 
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(Figure 4.1). Normally, GSSG is then reduced back to GSH by glutathione 
reductase, but under oxidative stress, there is an accumulation of the oxidized 
form.27 Not only does the accumulation of GSSG activate nuclear factor kappa B 
(NF-κB) causing stress and inflammatory response, but the inability for GSSG to 
convert back to GSH can cause other detrimental factors. These responses have 
been implicated in many diseases including Parkinson’s.27,40 Thus, glutathione 
has shown to be a potential biomarker in many diseases. In chapter 3, the 
fungicide Ziram was investigated and glutathione was identified as a good 
endogenous biomarker to detect the fungicide in further studies. In this 
experiment, we investigated a method to determine glutathione’s binding to 
Ziram using High Performance Liquid Chromatography-Mass Spectrometry.   
 
 MATERIALS AND METHODS 
The Shimadzu Nexera Liquid Chromtography system coupled to the 
Thermo Q-Exactive Orbitrap Mass Spectrometer was used. Both infusion and the 
HPLC were utilized. The column used for the HPLC was a Kromasil Eternity XT-
2.5-C18 column with dimensions 2.1 x 100 mm. The QE infusion parameters 
were similar to those referenced in chapter 3. When the LC was utilized the spray 
voltage was 3 kV, the source current was 6.5-7 μA, the auxiliary sheath gas flow 
was 10 arbitrary units, and a flow rate of 3 μL per minute. 
 
 Derivatization of glutathione with N-ethylmaleimide 
Following the protocol by Giustarini et al, N-ethylmaleimide (500 μL of 155 
mM) was combined with GSH (500 μL of 8 mM) in 50:50 MeOH:H2O and allowed 
42 
 
to sit in the dark at room temperature for 45 minutes.41 The solution was diluted 
by 100 and 1000 before infusion on the Q-Exactive. The NEM was later diluted to 
50 mM and combined that with the 8 mM GSH before incubating in the dark at 
room temperature for 45 minutes. At time intervals of 5, 15, 30, and 45 minutes, 
10 μL of the solution was removed, diluted to 1000 μL 50:50 MeOH:H2O, and 
infused on the Q-Exactive.  
To determine if NEM would remove ZIR from GSH, a 1 mg/mL solution of 
GSH-ZIR was first infused on the Q-Exactive for a control. Then, an equal 
amount of NEM was added to the GSH-ZIR solution and allowed to sit at room 
temperature in the dark for 45 minutes before infusion.  
 
 Extraction optimization and HPLC run 
The preliminary extraction was 50 μL GSH-ZIR-NEM solution, 50 μL 
acetonitrile, and 50 μL serum. Then the extraction included 50 μL GSH-ZIR, 50 
μL glutathione-NEM (GSH-NEM), 50 μL 500 mM ammonium acetate, 50 μL 
serum, and 100 μLacetonitrile. Final extraction ratio was 50 μL GSH-ZIR, 50 μL 
GSH-NEM, 50 μL glutathione ethyl ester-NEM (GSE-NEM), 50 μL serum, 50 μL 
500 mM ammonium acetate, and 50 μL 10% trichloroacetic acid (TCA). All 
extractions were vortexed and centrifuged at 13.2 g in a microcentrifuge for 10 
minutes. Supernatants were then collected into autosampler vials and injected on 
the HPLC.  
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For the LC run, the mobile phases were water with 0.1% formic acid as 
mobile phase A and acetonitrile with 0.1% formic acid as mobile phase B. The 
time gradient is seen in Table 4.1 and the flow rate was 0.3 mL/min. 
Table 4.1 HPLC time gradient 
Time Mobile phase B % 
0 min 5% 
5 min 5% 
7min 95% 
10 min 95% 
11 min 5% 
15 min Stop 
 
 Validation 
For the method detection limit, we followed the protocol set by the 
Environmental Protection Agency.42 Using the extraction method determined 
earlier, we spiked in 50 nM GSH-ZIR, 50 nM GSH-NEM, and 50 μM GSE-NEM 
into serum for seven replicates on three separate days. We also included seven 
method blanks with each run. To determine the curves for both compounds, at 
least five points in the range of 5 nM to 2 mM were evaluated over at least three 
days.  
 
 RESULTS AND DISCUSSION 
 Derivatization of glutathione with N-ethylmaleimide 
In previous studies, glutathione has been noted to auto-oxidize to the 
disulfide form in biological matrices.43 Because of this phenomenon, accurately 
measuring the total levels of GSH can be difficult. In the Camera et al. review, 
they discuss different studies that have dealt with the auto-oxidation issue with 
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GSH.43 Some studies derivatized glutathione, reduced all oxidized glutathione 
back to the reduced form, and others have forced the oxidation among other 
potential pathways to account for measuring GSH levels. In this experiment, 
similarly to chapter 2 with homocysteine, we decided to use the reducing and 
derivatizing agent NEM. NEM has been shown in previous studies to essentially 
force the disulfide back into the reduced form and prevent any free GSH from 
auto-oxidizing in solution.44  
After following the Giustarini et al. protocol where 155 mM of NEM was 
reacted with 8 mM GSH and infused on the Q-Exactive, there was no indicative 
oxidized glutathione peak (m/z 613.15).41 However, there was a large peak of 
NEM (m/z 126.05) indicating that there was too much NEM in the solution. It 
made sense that there was a plethora of NEM leftover since the ratio of GSH to 
NEM was roughly 1:100. Because of the high amount of NEM left over in 
solution, the ratio of GSH to NEM was lowered to about 1:5 with 8 mM GSH and 
50 mM NEM.  
After 8 mM GSH was reacted with 50 mM NEM, we wanted to determine 
the earliest incubation time needed to see GSH and NEM reacting. The solution 
sat at room temperature in the dark for 45 minutes with 10 μL removed at 5, 15, 
30, and 45 minutes. The indicative peak of the GSH-NEM (Figure 4.2a) 
compound (433.13 m/z) was seen as early as five minutes (Figure 4.2b). 
However, at the same time, the NEM molecular ion m/z 126.05 (Figure 4.3) was 
more abundant than the GSH-NEM ion. As the incubation time went on, the ratio 
of the ions switched to where the GSH-NEM ion became more abundant than the 
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NEM ion (Figure 4.2b and 4.3). Because the ratio was still 1:5 with an excess of 
NEM, the NEM ion was still seen at the 45-minute mark, but just less abundant 
than at the five-minute mark. The potential auto-oxidation of GSH was also 
confirmed to not occur at any time point, proving that while NEM was in the 
sample, GSSG did not appear (Figure 4.4). Although GSH-NEM was seen as 
early as five-minute, to ensure that the GSH was fully reacting with NEM before 
any analysis took place, all further GSH-NEM solutions were given at least 45 
minutes incubation time in the dark at room temperature.  
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Figure 4.2 a) Structure of GSH-NEM and b) Mass spectra of GSH-NEM ion 
433.13 at 5, 15, 30, and 45 min 
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Figure 4.3 Mass spectra of NEM ion 126.05 at 5, 15, 30, and 45 min 
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Figure 4.4 Mass spectra of GSSG 613.15 at 5, 15, 30, and 45 min 
 
One thing we had to take into consideration was how NEM would interact 
with the GSH-ZIR solution, since NEM is known to break disulfide bonds. After 
seeing that GSH-ZIR and GSH-NEM on the instrument individually, we took 
GSH-ZIR and added NEM in equal amounts to ZIR. No matter how long the 
solution was left to react, we did not see a reduction in GSH-ZIR along with an 
increase in GSH-NEM (Figure 4.5, 4.6, 4.7, and 4.8). However, most of the 
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solutions made had an excess of Ziram, so there were some peaks indicating 
that Ziram bonded to NEM separately. Although these Ziram-NEM peaks did not 
seem to affect the results, we used the GSH-NEM and GSH-ZIR reacted 
solutions for validation purposes.  
 
Figure 4.5 Mass spectra of GSH-ZIR ion 427.07 before and after addition of NEM 
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Figure 4.6 Mass spectra of glutathione ion 308.09 before and after addition of 
NEM 
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Figure 4.7 Mass spectra of NEM-ZIR ion 247.05 before and after addition of NEM 
 
 
 
N
O
O HS
S
N
52 
 
 
Figure 4.8 Mass spectra of GSH-NEM ion 433.13 before and after addition of 
NEM 
 
 Extraction optimization and HPLC run 
When evaluating an extraction protocol, a few things had to be taken into 
consideration. In terms of the matrix used, the main consideration was how to 
actually remove the compounds from the matrix. In the review by Monostori et al, 
they discussed different extractions techniques that have been used to remove 
both reduced and oxidized glutathione from biological matrices.45 Overall, the 
general extraction methods discussed involved the matrix and compounds of 
interest and then some chemical or solution that would cause the proteins in the 
matrix to precipitate out. Based on the Monostori et al. review, acetonitrile 
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seemed like a viable starting point.45 The preliminary extraction used was 50 μL 
of a GSH-NEM-ZIR solution, 50 μL acetonitrile, and 50 μL serum. The solution 
was vortexed and centrifuged for 10 minutes before the supernatant was injected 
on the HPLC with a 50 mm C18 column with water with 0.1% formic acid and 
acetonitrile with 0.1% formic acid as the mobile phases. Because the compounds 
are fairly polar and the column was believed to be short, none of the compounds 
appeared in the chromatography.  After switching to a longer column (100 mm), 
the ions for the compounds were seen. The retention times were GSH (308.09 
m/z) at 3.65 and 4.31 min, GSH-NEM (433.13 m/z) at 3.63 and 4.32 min, and 
GSH-ZIR (433.13 m/z) at 7.36 min. Because the GSH and GSH-NEM peaks 
split, parts of the HPLC run were evaluated. However, some literature has 
reported that GSH-NEM causes split peaks due to the isomers forming from how 
the NEM attaches to the GSH.46     
Other studies believed that the split peaks were caused by something in the 
extraction, so a buffer was included to balance out the pH.45 Ammonium acetate 
was chosen as the buffer, which led to the extraction being 50 μL 500 mM 
ammonium acetate,  50 μL of each compound, 50 μL serum, and 100 μL 
acetonitrile for a total of 300 μL solution. After ammonium acetate was added, the 
supernatant appeared more clear than before. In addition, the HPLC flow rate 
was lowered to 0.2 mL/min to see if that also would help in the chromatography 
of the molecules. The chromatography was a little bit cleaner, but the peak for 
GSH-NEM was still split. The split peaks were still attributed to the isomers of 
GSH-NEM. Looking forward to being able to quantitate the molecules a little 
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better, a tandem experiment was done on the molecular weight ions of 427.07 
m/z and 433.13 m/z for GSH-ZIR and GSH-NEM, respectively. The major 
tandem ion for 427.07 was 251.08, as seen in Figure 4.9. The major tandem ions 
for 433.13 are seen in Figure 4.10.   
 
Figure 4.9 Tandem spectrum of GSH-ZIR m/z 427.07 
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Figure 4.10 Tandem spectrum of GSH-NEM m/z 433.13 
 
Although GSH-ZIR and GSH-NEM were qualitatively seen, to add an extra 
layer of sensitivity, an internal standard was evaluated to effectively quantitate 
the two compounds. When looking for an internal standard, one should be as 
physiochemically similar to the compound of interest and added to both 
calibrators and samples at a known constant concentration to be able to use as a 
comparison for the compound in question.26 An internal standard allows for any 
type of error that could affect the variability between samples to be removed 
because what happens to the molecule of interest should also occur to the 
internal standard. Preferentially, an isotopically-labelled version of the molecule 
in question should be used. In this study, we were unable to use an isotopically 
labelled glutathione; however, we were able to use a similar compound, 
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glutathione ethyl ester (GSE). The only difference between GSH and GSE is 
instead of a carboxylic acid on the glycine end there is an ethyl ester (see Figure 
4.11). Because of this being the only difference, both compounds are very similar 
physiochemically. This also caused pause because of the reactive thiol group. 
GSE was also derivatized with NEM to ensure that there were no interactions 
between GSE and any other thiols, like GSH. When GSE was derivatized with 
NEM, the molecular weight was 460.05 g/mol. The derivatization also allowed 
GSE-NEM to more closely resemble GSH-NEM and all previous protocols for 
derivatizing GSH with NEM was used to derivatize GSE with NEM. One issue 
that was noted was that when tandem experiments were done on GSH-NEM and 
GSE-NEM, similar tandem spectra was seen. Because of the ethyl ester instead 
of the carboxylic acid, the main fragment ion for GSE-NEM was 315.10, which 
was not seen in the GSH-NEM tandem spectrum and thus taken into 
consideration with any tandem quantitation (Figure 4.12).   
 
Figure 4.11 Structure of GSH (top) and GSE (bottom) 
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Figure 4.12 Tandem spectrum of GSE-NEM m/z ion 461.17 
 
After the addition of the internal standard, the split peaks were reevaluated. 
The HPLC parameters of the flow rate, mobile phases, and gradient were first 
investigated to see if that would change the chromatography. The flow rate was 
adjusted to 0.3 mL/min, 0.2 mL/min, and 0.25 mL/min. The change in flow rate 
did not help the split peaks issue but only changed the retention times. For the 
mobile phase, the formic acid was removed from mobile phase B. There was one 
sample where the GSE-NEM did not have split peaks but the GSH-NEM still did. 
In future work, we may look at removing the formic acid from both mobile phases. 
Since the molecules eluted within ten minutes, the gradient was not adjusted 
drastically. Even changing the starting conditions to 10% mobile phase B did not 
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resolve the split peak issue. Because the HPLC settings did not seem to affect 
the chromatography, the extraction parameters were evaluated some more.  
First, the buffer was evaluated. Ammonium acetate (pH 6.4) and sodium 
phosphate buffer (pH 7.2) were investigated as potential buffers. When the 
sodium phosphate buffer was used in the extraction, the peaks did not split, but 
the GSH-NEM and GSH-ZIR came out in the void volume. The sodium in the 
buffer most likely created an adduct with the compounds. To prevent adduct 
formation and since the chromatography was poor, ammonium acetate was still 
used in the extractions. The extraction ratio of ammonium acetate to acetonitrile 
was then assessed. The ratios of ammonium acetate to acetonitrile were 1:2, 1:1, 
and 2:1. With the 2:1 ratio, the GSH-NEM and GSH-ZIR still had two peaks, but 
were baseline resolved. GSE-NEM still had split peaks, especially near the later 
samples. Even though a couple runs would appear okay, the samples were not 
reproducible enough to stick with a particular extraction. Previous studies have 
used other protein precipitation solvents, like sulfosalicylic acid and 
trichloroacetic acid, usually at a concentration of 10%.41 We included some of the 
changes that were previously investigated with 10% trichloroacetic acid (TCA). A 
majority of the chromatograms for the different extraction types are in Figure 4.13 
for GSH-ZIR, Figure 4.14 for GSE-NEM, and Figure 4.15 for GSH-NEM. Over all 
three compounds, the best chromatography came from the extraction that 
involved 50 μL of each compound, 50 μL 500 mM ammonium acetate, 50 μL 
serum, and 50 μL 10% TCA. The retention times were around 7.30 minutes for 
GSH-ZIR, 5.50 minutes for GSH-NEM, and 7.60 minutes for GSE-NEM. 
59 
 
 
Figure 4.13 Chromatograms of different extractions for GSH-ZIR. a) original 
extraction, no TCA; b) TCA without acetonitrile; c) TCA with acetonitrile; d) TCA, 
sodium phosphate buffer, no acetonitrile; e) TCA, sodium phosphate buffer, 
acetonitrile; f) TCA, acetonitrile, formic acid in mobile phase; g) TCA, no 
acetonitrile, formic acid in mobile phase 
a) 
b) 
c) 
d) 
e) 
f) 
g) 
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Figure 4.14 Chromatograms of different extractions for GSH-NEM. a) original 
extraction, no TCA; b) TCA without acetonitrile; c) TCA with acetonitrile; d) TCA, 
sodium phosphate buffer, no acetonitrile; e) TCA, sodium phosphate buffer, 
acetonitrile; f) TCA, acetonitrile, formic acid in mobile phase; g) TCA, no 
acetonitrile, formic acid in mobile phase 
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Figure 4.15 Chromatograms of different extractions for GSE-NEM. a) original 
extraction, no TCA; b) TCA without acetonitrile; c) TCA with acetonitrile; d) TCA, 
sodium phosphate buffer, no acetonitrile; e) TCA, sodium phosphate buffer, 
acetonitrile; f) TCA, acetonitrile, formic acid in mobile phase; g) TCA, no 
acetonitrile, formic acid in mobile phase 
 
 Validation 
Glutathione has previously been detected at levels in biological matrices 
ranging from low micromolar range to low millimolar range.10,41 However, since 
most of the research with Ziram is via epidemiology studies and there is no 
definitive concentration seen consistently in biological matrices, we erred on the 
side of caution and decided to try to detect in the nanomolar range with GSH-ZIR 
and GSH-NEM. Although GSH is normally in the micromolar range, being able to 
detect GSH-ZIR at lower levels could potentially lead to early detection of 
diseases caused by Ziram.  
g) 
f) 
e) 
d) 
c) 
b) 
a) 
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For the calibration curve, we wanted to cover a large range of values, so 
we created a curve from 5 nM to 2 mM. For both GSH-ZIR and GSH-NEM, 50 
uM of GSE-NEM was used as the internal standard concentration. At first nine 
points were used for the calibration curve, but after removing outliers, a six-point 
curve was used for the GSH-NEM curve. The points were 5 nM, 100 nM, 500 
nM, 1 μM, 100 μM, and 500 μM. Because normal GSH ranges do not go very 
high, only up to 500 μM was included in the curve. There was a curve done on 
three different days to account for inter-day variability. For GSH-NEM, the 
averaged calibration points gave a curve with a R2 value of 0.9998, as seen in 
Figure 4.16.  
 
 
Figure 4.16 Calibration curve of GSH-NEM  
 
The next validation parameter that was evaluated was the method 
detection limit (MDL). The MDL is described “as the minimum measured 
concentration of a substance that can be reported with 99% confidence that the 
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measured concentration is distinguishable from method blank results.”42 This is 
done by spiking anywhere from two to 10 times the amount of the limit of 
detection (LOD) in the matrix of choice for seven replicates over three days. The 
method detection limit is then calculated by the spiked standard deviation value 
times the student t-value at the 99% confidence interval. Because our intended 
LOD was set to 5 nM, the spiked concentration used was 50 nM. For the purpose 
of the MDL, the samples were ran in full scan. The method detection limit for 
GSH-NEM was determined to be 1.47 μM. The ratio of area counts of 433.13 to 
461.16 was first determined over at least 3 days. Those values were then solved 
for the concentration based on the calibration curve equation of 
y=0.0027x+0.0015 (Figure 4.16) where y is the ratio and x is the concentration. 
Each day’s seven samples were then averaged and the standard deviation was 
taken (Ss). This standard deviation was then multiplied by 3.143 which is the 99% 
confidence level of the student’s t-test with n=7 (Equation 1). Each one of those 
values was then averaged giving the 1.47 μM. This procedure was also done for 
seven blanks over at least three separate days (Equation 2). The standard 
deviation of the blanks was multiplied by the 3.143 value again and added to the 
average concentration of the blanks. Whichever value was highest, the MDLs or 
MDLb,was the given method detection limit. For GSH-NEM, the blanks gave a 
negative value, making 1.47 μM the method detection limit. 
𝑀𝑀𝑀𝑀𝑀𝑀𝑠𝑠 = 𝑡𝑡(𝑛𝑛−1,1−𝛼𝛼=.99)𝑆𝑆𝑠𝑠       (𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑡𝑡𝑖𝑖𝑖𝑖𝑖𝑖 1) 
𝑀𝑀𝑀𝑀𝑀𝑀𝑏𝑏 = 𝑋𝑋� + 𝑡𝑡(𝑛𝑛−1,1−𝛼𝛼=.99)𝑆𝑆𝑏𝑏      (𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝑡𝑡𝑖𝑖𝑖𝑖𝑖𝑖 2) 
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 CONCLUSION 
In this study, further investigation of glutathione and Ziram occurred. Similarly 
to chapter 2 about homocysteine, N-ethylmaleimide was used as a derivatizing 
agent to prevent the auto-oxidation of GSH in biological matrices. Although GSH-
ZIR and GSH-NEM were seen with sufficient reproducibility, glutathione ethyl 
ester was implemented as an internal standard to account for any variability 
between samples. To prevent the cysteine from reacting with free thiols, GSE 
was also derivatized with NEM. Using GSE-NEM as the internal standard, the 
extraction method and HPLC parameters were evaluated to create a better 
extraction and to potentially prevent split peaks that were seen with GSH-NEM. 
Although the extraction was somewhat cleaned up and the split peaks were 
resolved in some samples, further work should be done to complete this 
optimization. After the initial optimization, the method validation began. There 
were some issues with validating GSH-ZIR, so we worked on validating GSH-
NEM. A curve from 5 nM to 500 μM was created with a R2 value of 0.9998. The 
method detection limit for GSH-NEM was also evaluated and determined to be 
1.47 μM. Further validation parameters would need to be evaluated and a full 
validation of GSH-ZIR is also needed in future work.    
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CHAPTER 5. CONCLUSIONS AND FUTURE WORK 
As people become more aware of the impact that environmental exposures 
have on their overall health, there is a growing need to be at the forefront to 
determine potential biomarkers for the development of diseases. In this work, two 
endogenous biomolecules that have been implicated in the development of 
diseases and disorders were investigated. The first was homocysteine, which 
was successfully identified via capillary electrophoresis. Because it was hard to 
differentiate between similar thiol-containing amino acids, homocysteine was 
derivatized with 4-vinyl pyridine and N-ethylmaleimide. The derivatization with 
NEM was confirmed via capillary electrophoresis-mass spectrometry. The other 
endogenous biomarker was glutathione, the most abundant low-molecular weight 
thiol-containing molecule. First, glutathione was shown to bind to the fungicide 
Ziram via the cysteine thiol. Because Ziram is a part of the larger dithiocarbamate 
family, this work could lead to further studies on these compounds. An extraction 
protocol was evaluated, and early validation was done for GSH-ZIR, GSH-NEM, 
and the internal standard glutathione ethyl ester-NEM in serum. Like 
homocysteine, GSH was derivatized with NEM to account for extra GSH in 
biological matrices. The internal standard GSE was also derivatized with NEM to 
prevent any bonding with GSH or other thiols. A curve for GSH-NEM was 
developed from 5 nanomolar to 500 micromolar. The method detection limit was 
determined at the 5 nanomolar level to be 1.47 micromolar.  
 For future work, more work should be done on homocysteine. Potentially, 
a method could be developed and validated for homocysteine. Although Ziram 
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was only looked at in terms of glutathione, more work could be done to look at 
other endogenous biomarkers, like homocysteine, and how Ziram interacts with 
them, leading to diseases. Further validation needs to be done on GSH-NEM and 
GSH-ZIR. Other biological matrices and fungicides would be investigated and 
validated, including blood and plasma. After development of the methods, the 
long-term goal was to investigate the connection of these environmental 
exposures, endogenous biomarkers, and the development of diseases. This work 
is a starting point for many more exposure studies to potentially help people be 
more aware of how their environment can affect their health and have the 
potential for disease development throughout their life.  
 
  
67 
 
REFERENCES 
(1)  Wild, C. P. Complementing the Genome with an “Exposome”: The Outstanding 
Challenge of Environmental Exposure Measurement in Molecular Epidemiology. 
Cancer Epidemiol. Biomarkers Prev. 2005, 14 (8), 1847–1850. 
https://doi.org/10.1158/1055-9965.EPI-05-0456. 
(2)  Wild, C. P. The Exposome: From Concept to Utility. Int. J. Epidemiol. 2012, 41, 
24–32. https://doi.org/10.1093/ije/dyr236. 
(3)  Vrijheid, M. The Exposome: A New Paradigm to Study the Impact of Environment 
on Health. Thorax 2014, 69, 876–878. https://doi.org/10.1136/thoraxjnl-2013-
204949. 
(4)  Rappaport, S. M.; Smith, M. T. Environment and Disease Risks. New Ser. 2010, 
330 (6003), 460–461. https://doi.org/10.1111/J.1558-5646.2010.01045.X. 
(5)  Rappaport, S. M. Biomarkers Intersect with the Exposome. Biomarkers 2012, 17 
(6), 483–489. https://doi.org/10.3109/1354750X.2012.691553. 
(6)  Ray, S.; Reddy, P. J.; Jain, R.; Gollapalli, K.; Moiyadi, A.; Srivastava, S. 
Proteomic Technologies for the Identification of Disease Biomarkers in Serum: 
Advances and Challenges Ahead. Proteomics 2011, 11, 2139–2161. 
https://doi.org/10.1002/pmic.201000460. 
(7)  Group, B. D. W. Biomarkers and Surrogate Endpoints: Preferred Definitions and 
Conceptual Framework. Clin. Pharmacol. Ther. 2001, 69 (3), 89–95. 
https://doi.org/10.1067/mcp.2001.113989. 
(8)  Demaagd, G.; Philip, A. Parkinson’s Disease and Its Management Part 1: 
Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and 
Diagnosis. Pharm. Ther. 2015, 40 (8), 504–511. 
(9)  Hannibal, L.; Blom, H. J. Homocysteine and Disease: Causal Associations or 
Epiphenomenons? Mol. Aspects Med. 2017, 53, 36–42. 
https://doi.org/10.1016/j.mam.2016.11.003. 
(10)  Smeyne, M.; Smeyne, R. J. Glutathione Metabolism and Parkinson’s Disease. 
Free Radic. Biol. Med. 2013, 62, 13–25. 
https://doi.org/10.1016/j.freeradbiomed.2013.05.001. 
(11)  Copper, C. L. Capillary Electrophoresis Part I . Theoretical and Experimental 
Background. J. Chem. Educ. 1998, 75 (3), 343–347. 
(12)  Li, S. F. Y.; Wu, Y. S. Capillary Electrophoresis. In Electrophoresis; 2000; pp 
1176–1187. https://doi.org/10.1021/ac00171a002. 
(13)  Niessen, W. M. A. Introduction To Liquid Chromatography. In Liquid 
Chromatography-mass Spectrometry; 1999; pp 3–30. 
https://doi.org/10.1016/b978-0-12-732052-6.50007-9. 
68 
 
(14)  Moldoveanu, S.; David, V. Basic Information about HPLC. In Essentials in 
modern HPLC separations; 2013; pp 1–51. https://doi.org/10.1016/B978-0-12-
385013-3.00001-X. 
(15)  Covey, T. R.; Thomson, B. A.; Schneider, B. B. Atmospheric Pressure Ion 
Sources. Mass Spectrom. Rev. 2009, 28 (6), 870–897. 
https://doi.org/10.1002/mas.20246. 
(16)  Skoog, D. A.; Holler, F. J.; Crouch, S. R. Principles of Instrumental Analysis, 6th 
ed.; 2017. 
(17)  Banerjee, S.; Mazumdar, S. Electrospray Ionization Mass Spectrometry: A 
Technique to Access the Information beyond the Molecular Weight of the 
Analyte. Int. J. Anal. Chem. 2012, 2012, 1–40. 
https://doi.org/10.1155/2012/282574. 
(18)  Blom, H. J.; Smulders, Y. Overview of Homocysteine and Folate Metabolism. 
With Special References to Cardiovascular Disease and Neural Tube Defects. J. 
Inherit. Metab. Dis. 2011, 34 (1), 75–81. https://doi.org/10.1007/s10545-010-
9177-4. 
(19)  Selhub, J. HOMOCYSTEINE METABOLISM. Annu. Rev. Nutr. 1999, 19, 217–
246. 
(20)  Schalinske, K. L.; Smazal, A. L. Homocysteine Imbalance: A Pathological 
Metaboli Marker. Adv. Nutr. 2012, 3, 755–762. 
https://doi.org/10.3945/an.112.002758.Figure. 
(21)  Yuyun, M. F.; Ng, L. L.; Ng, G. A. Endothelial Dysfunction, Endothelial Nitric 
Oxide Bioavailability, Tetrahydrobiopterin, and 5-Methyltetrahydrofolate in 
Cardiovascular Disease. Where Are We with Therapy? Microvasc. Res. 2018, 
119 (September 2017), 7–12. https://doi.org/10.1016/j.mvr.2018.03.012. 
(22)  Kumar, A.; Palfrey, H. A.; Pathak, R.; Kadowitz, P. J.; Gettys, T. W.; Murthy, S. 
N. The Metabolism and Significance of Homocysteine in Nutrition and Health. 
2017, 14 (78), 1–12. https://doi.org/10.1186/s12986-017-0233-z. 
(23)  Duan, W.; Ladenheim, B.; Cutler, R. G.; Kruman, I. I.; Cadet, J. L.; Mattson, M. P. 
Dietary Folate Deficiency and Elevated Homocysteine Levels Endanger 
Dopaminergic Neurons in Models of Parkinson’s Disease. J. Neurochem. 2002, 
80, 101–110. 
(24)  Isobe, C.; Murata, T.; Sato, C.; Terayama, Y. Increase of Total Homocysteine 
Concentration in Cerebrospinal Fluid in Patients with Alzheimer’s Disease and 
Parkinson’s Disease. Life Sci. 2005, 77, 1836–1843. 
https://doi.org/10.1016/j.lfs.2005.02.014. 
(25)  Hudson, J. C. CESI-MS Analysis of Biofl Uids of Basic Drugs and Metabolites. 
(26)  Kusmierek, K.; Chwatko, G.; Głowacki, R.; Kubalczyk, P.; Bald, E. Ultraviolet 
Derivatization of Low-Molecular-Mass Thiols for High Performance Liquid 
Chromatography and Capillary Electrophoresis Analysis. J. Chromatogr. B 2011, 
69 
 
879, 1290–1307. https://doi.org/10.1016/j.jchromb.2010.10.035. 
(27)  Rath, N. C.; Rasaputra, K. S.; Liyanage, R.; Huff, G. R.; Huff, W. E. 
Dithiocarbamate Toxicity-An Appraisal. In Pesticides in the Modern World-Effects 
of Pesticides Exposure; Stoytcheva, M., Ed.; InTech, 2011; pp 323–340. 
(28)  Programs, O. of P. The Grouping of a Series of Dithiocarbamate Pesticides 
Based on a Common Mechanism of Toxicity Mn; 2001. 
(29)  Chou, A. P.; Maidment, N.; Klintenberg, R.; Casida, J. E.; Li, S.; Fitzmaurice, A. 
G.; Fernagut, P.-O.; Mortazavi, F.; Chesselet, M.-F.; Bronstein, J. M. Ziram 
Causes Dopaminergic Cell Damage by Inhibiting E1 Ligase of the Proteasome. 
J. Biol. Chem. 2008, 283 (50), 34696–34703. 
https://doi.org/10.1074/jbc.M802210200. 
(30)  Lulla, A.; Barnhill, L.; Bitan, G.; Ivanova, M. I.; Nguyen, B.; O’Donnell, K.; Stahl, 
M. C.; Yamashiro, C.; Klärner, F.-G.; Schrader, T.; et al. Neurotoxicity of the 
Parkinson Disease-Associated Pesticide Ziram Is Synuclein-Dependent in 
Zebrafish Embryos. Environ. Health Perspect. 2016, 124 (11), 17661775. 
https://doi.org/10.1289/EHP141. 
(31)  Kawakishi, S.; Kaneko, T. Interaction of Oxidized Glutathione with Allyl 
Isothiocyanate. Phytochemistry 1985, 24 (4), 715–718. 
https://doi.org/10.1016/S0031-9422(00)84882-7. 
(32)  Resource, W. P. Protein Reduction, Alkylation, Digestion; pp 1–8. 
(33)  Crnogorac, G.; Schwack, W. Residue Analysis of Dithiocarbamate Fungicides. 
Trends Anal. Chem. 2009, 28 (1), 40–50. 
https://doi.org/10.1016/j.trac.2008.10.008. 
(34)  Meister, A. Glutathione Metabolism and Its Selective Modification. J. Biol. Chem. 
1988, 263 (33), 17205–17208. 
(35)  Sies, H. Glutathione and Its Role in Cellular Functions. Free Radic. Biol. Med. 
1999, 27 (9), 916–921. 
(36)  Meister, A.; Anderson, M. E. Glutathione. Annual 1983, 52, 711–760. 
(37)  Meister, A. Glutathione Metabolism. In Methods in Enzymology; 1995; Vol. 251, 
pp 3–7. 
(38)  Forman, H. J.; Zhang, H.; Rinna, A. Glutathione: Overview of Its Protective 
Roles, Measurement, and Biosynthesis. Mol. Aspects Med. 2009, 30 (1–2), 1–12. 
https://doi.org/10.1016/j.mam.2008.08.006. 
(39)  Wu, G.; Fang, Y.-Z.; Yang, S.; Lupton, J. R.; Turner, N. D. Glutathione 
Metabolism and Its Implications for Health. J. Nutr. 2004, 134 (3), 489–492. 
https://doi.org/10.1093/jn/134.3.489. 
(40)  Martin, H. L.; Teismann, P. Glutathione — a Review on Its Role and Significance 
in Parkinson ’ s Disease. Fed. Am. Soc. Exp. Biol. 2009, 23 (10), 3263–3272. 
70 
 
https://doi.org/10.1096/fj.08-125443. 
(41)  Giustarini, D.; Dalle-Donne, I.; Milzani, A.; Fanti, P.; Rossi, R. Analysis of GSH 
and GSSG after Derivatization with N-Ethylmaleimide. Nat. Protoc. 2013, 8 (9), 
1660–1669. https://doi.org/10.1038/nprot.2013.095. 
(42)  Agency, U. S. E. P. Definition and Procedure for the Determination of the Method 
Detection Limit, Revision 2; 2016. 
(43)  Camera, E.; Picardo, M. Analytical Methods to Investigate Glutathione and 
Related Compounds in Biological and Pathological Processes. J. Chromatogr. B 
2002, 781, 181–206. 
(44)  Giustarini, D.; Dalle-Donne, I.; Milzani, A.; Rossi, R. Detection of Glutathione in 
Whole Blood after Stabilization with N-Ethylmaleimide. Anal. Biochem. 2011, 415 
(1), 81–83. https://doi.org/10.1016/j.ab.2011.04.013. 
(45)  Monostori, P.; Wittmann, G.; Karg, E.; Túri, S. Determination of Glutathione and 
Glutathione Disulfide in Biological Samples: An in-Depth Review. J. Chromatogr. 
B Anal. Technol. Biomed. Life Sci. 2009, 877, 3331–3346. 
https://doi.org/10.1016/j.jchromb.2009.06.016. 
(46)  Sutton, T. R.; Minnion, M.; Barbarino, F.; Koster, G.; Fernandez, B. O.; 
Cumpstey, A. F.; Wischmann, P.; Madhani, M.; Frenneaux, M. P.; Postle, A. D.; 
et al. A Robust and Versatile Mass Spectrometry Platform for Comprehensive 
Assessment of the Thiol Redox Metabolome. Redox Biol. 2018, 16 (February), 
359–380. https://doi.org/10.1016/j.redox.2018.02.012. 
 
71 
 
 
VITA 
Tracy Allison Gastineau-Stevens 
 
PLACE OF BIRTH 
 
Houston, Texas 
 
EDUCATION 
 
Bachelor of Science in Chemistry and Biology, Houston Baptist University, 
Houston, TX, 2011 
 
Master of Science in Forensic Science, Sam Houston State University, 
Huntsville, TX, 2014 
 
PROFESSIONAL EXPERIENCE 
 
Graduate Assistant, Mass Spectrometry Facility, University of Kentucky, 
Lexington, KY, May 2018-present 
 
Graduate Teaching Assistant, University of Kentucky, Lexington, KY, August 
2017-May 2018 
 
Forensic Toxicologist, Harris County Institute of Forensic Sciences, Houston, TX 
June 2014-August 2016 
 
Graduate Assistant, Sam Houston State University, Huntsville, TX, August 2012-
May 2014 
 
Undergraduate Researcher, Houston Baptist University, Houston, TX, August 
2010-May 2011 
 
Teaching Assistant, Houston Baptist University, Houston, TX, August 2008-May 
2011 
